Literature DB >> 23335103

Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma.

Lei Zhao1, Jin Yang, Hui-Ping Wang, Rong-Yu Liu.   

Abstract

It has been reported that the imbalance of T helper IL-17-producing cells (Th17 cells)/regulatory T cells (Tregs) was closely associated with advanced tumor growth and poor prognosis in lung cancer, but little is known about whether this imbalance is existed in the peripheral blood of patients with non-small cell lung cancer (NSCLC). Here, the percentage of Treg and Th17 cells, and the expression of transcription factors RORγt and FoxP3 were studied by flow cytometry, real-time PCR, and Western blotting, respectively. Levels of serum cytokines (IL-6, IL-17, IL-10, and TGF-β1) were analyzed by ELISA. The results showed that there was an increase in the percentage of Tregs, the mRNA and protein expression of FoxP3, the level of Treg-related cytokines in patients with NSCLC while compared to that in healthy patients. Moreover, the percentage of Th17 cells, RORγt mRNA, and protein expression were decreased in peripheral blood of NSCLC patients. In addition, Th17/Treg ratio was decreased in lung cancer patients when compared with healthy patients and Th17/Treg ratio was negatively correlated with the stages. Our results indicate that the Th17/Treg balance is abnormal in peripheral blood, which may be important in the development of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335103     DOI: 10.1007/s12032-013-0461-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

2.  CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.

Authors:  Riki Okita; Toshiaki Saeki; Shigemitsu Takashima; Yoshiyuki Yamaguchi; Tetsuya Toge
Journal:  Oncol Rep       Date:  2005-11       Impact factor: 3.906

3.  The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma.

Authors:  Wei-Chen Lee; Ting-Jung Wu; Hong-Shiue Chou; Ming-Chin Yu; Pao-Yueh Hsu; Hsiu-Ying Hsu; Chao-Ching Wang
Journal:  Surgery       Date:  2011-10-05       Impact factor: 3.982

Review 4.  Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Authors:  Joannes F M Jacobs; Stefan Nierkens; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Lancet Oncol       Date:  2012-01       Impact factor: 41.316

5.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

6.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

8.  FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

Authors:  Noritoshi Kobayashi; Nobuyoshi Hiraoka; Wataru Yamagami; Hidenori Ojima; Yae Kanai; Tomoo Kosuge; Atsushi Nakajima; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

9.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Authors:  Ilona Kryczek; Mousumi Banerjee; Pui Cheng; Linhua Vatan; Wojciech Szeliga; Shuang Wei; Emina Huang; Emily Finlayson; Diane Simeone; Theodore H Welling; Alfred Chang; George Coukos; Rebecca Liu; Weiping Zou
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

10.  Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma.

Authors:  Poonam Gaur; Gulam Abdul Qadir; Shilpy Upadhyay; Avadhesh Kumar Singh; Nootan Kumar Shukla; Satya Narayan Das
Journal:  Cell Oncol (Dordr)       Date:  2012-09-07       Impact factor: 6.730

View more
  15 in total

1.  IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer.

Authors:  Ran You; Francesco J DeMayo; Jian Liu; Sung-Nam Cho; Bryan M Burt; Chad J Creighton; Roberto F Casal; Donald R Lazarus; Wen Lu; Hui-Ying Tung; Xiaoyi Yuan; Andrea Hill-McAlester; Myunghoo Kim; Sarah Perusich; Loraine Cornwell; Daniel Rosen; Li-Zhen Song; Silke Paust; Gretchen Diehl; David Corry; Farrah Kheradmand
Journal:  Cancer Immunol Res       Date:  2018-04-13       Impact factor: 11.151

Review 2.  Th17 cells and Tregs: unlikely allies.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  J Leukoc Biol       Date:  2014-02-21       Impact factor: 4.962

Review 3.  Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment.

Authors:  Spiros A Vlahopoulos; Osman Cen; Nina Hengen; James Agan; Maria Moschovi; Elena Critselis; Maria Adamaki; Flora Bacopoulou; John A Copland; Istvan Boldogh; Michael Karin; George P Chrousos
Journal:  Cytokine Growth Factor Rev       Date:  2015-06-20       Impact factor: 7.638

4.  Effects of transcutaneous acupoint electrical stimulation on the imbalance of Th1, Th2, Th17 and Treg cells following thoracotomy of patients with lung cancer.

Authors:  Huaxing Wu; Kun Wang; Guixian Li; Dexin Meng; Jiacheng Han; Guonian Wang; Y U Li
Journal:  Exp Ther Med       Date:  2015-12-04       Impact factor: 2.447

Review 5.  Immunomethylomics: A Novel Cancer Risk Prediction Tool.

Authors:  Karl T Kelsey; John K Wiencke
Journal:  Ann Am Thorac Soc       Date:  2018-04

6.  Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Authors:  C A Carter; A Rajan; C Keen; E Szabo; S Khozin; A Thomas; C Brzezniak; U Guha; L A Doyle; S M Steinberg; L Xi; M Raffeld; Y Tomita; M J Lee; S Lee; J B Trepel; K L Reckamp; S Koehler; B Gitlitz; R Salgia; D Gandara; E Vokes; G Giaccone
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

7.  Prognostic Significance of the Systemic Inflammatory and Immune Balance in Alcoholic Liver Disease with a Focus on Gender-Related Differences.

Authors:  Beata Kasztelan-Szczerbińska; Agata Surdacka; Krzysztof Celiński; Jacek Roliński; Agnieszka Zwolak; Sławomir Miącz; Mariusz Szczerbiński
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

8.  Decreased IL-27 Negatively Correlated with Th17 Cells in Non-Small-Cell Lung Cancer Patients.

Authors:  Minchao Duan; Zhengqing Ning; Zhijun Fu; Jianquan Zhang; Guangnan Liu; Qiu Wei; Xiaoyu Zheng
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

9.  LAP TGF-Beta Subset of CD4(+)CD25(+)CD127(-) Treg Cells is Increased and Overexpresses LAP TGF-Beta in Lung Adenocarcinoma Patients.

Authors:  Lorenzo Islas-Vazquez; Heriberto Prado-Garcia; Dolores Aguilar-Cazares; Manuel Meneses-Flores; Miriam Galicia-Velasco; Susana Romero-Garcia; Catalina Camacho-Mendoza; Jose Sullivan Lopez-Gonzalez
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

Review 10.  Fast food fever: reviewing the impacts of the Western diet on immunity.

Authors:  Ian A Myles
Journal:  Nutr J       Date:  2014-06-17       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.